Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.37 |
| ▸ | PDE5A | O76074 | 5/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161333 | 0.90 | GUCY1A1 (0.45) | L3MBTL1GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL20139738 | 0.87 | GUCY1A1 (0.35) | L3MBTL1GUCY1A1GUCY1B1PDE5ARET | |
| SCHEMBL21787437 | 0.85 | PDE5A (0.43) | L3MBTL1GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL21787225 | 0.82 | L3MBTL1 (0.60) | L3MBTL1GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL21787236 | 0.81 | L3MBTL1 (0.47) | L3MBTL1PDE5A | |
| SCHEMBL21787195 | 0.81 | L3MBTL1 (0.44) | L3MBTL1GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL20140411 | 0.81 | L3MBTL1 (0.46) | L3MBTL1PDE5A | |
| SCHEMBL21787238 | 0.81 | L3MBTL1 (0.49) | L3MBTL1PDE5A | |
| SCHEMBL24040769 | 0.80 | PDE5A (0.44) | L3MBTL1PDE5A | |
| SCHEMBL24205908 | 0.79 | L3MBTL1 (0.44) | L3MBTL1GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.